Phase II Trial of RAD001 (Everolimus) in Previously Treated Small Cell Lung Cancer
Status:
Completed
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
This is a phase II, two-stage, open-label, single-agent study of the experimental drug RAD001
(everolimus) in patients with previously treated small cell lung cancer. RAD001 will be
administered orally at a dose of 10 mg daily.